GoodRx reports Q3 adjusted EPS 8c, consensus 9c

Reports Q3 revenue $196M, consensus $194.51M. “GoodRx (GDRX) delivered another quarter of strong execution and meaningful progress across our strategic priorities,” said Wendy Barnes, Chief Executive Officer and President of GoodRx. “We expanded our manufacturer partnerships, launched innovative pharmacy counter solutions, and strengthened our brand as the most trusted name in prescription access and affordability. We also engaged meaningfully with the Presidential administration, helping to inform policy efforts that expand access and affordability for all Americans. Even amid a dynamic healthcare environment, our platform continues to demonstrate its power and relevance, delivering real value to consumers, pharmacies, and manufacturers, and positioning GoodRx for sustainable, long-term growth.”